On January 1, private coverage purchased through the state and federal health care exchanges will be taking effect, assuming consumers were able to navigate the bevy of technical glitches that plagued the federal system.
According to the Obama administration, more than 1.1 million people enrolled in coverage through the federal exchange site between October 1 and December 24, the last day that consumers could sign up and still receive coverage effective January 1.
That figure comes just shy of 1.2 million people the administration originally projected would sign up, but it also doesn’t include enrollment numbers from states that run their own exchanges or an estimate of how many Americans signed up for coverage under the expanded Medicaid program. That said, in early December the administration estimated that at least 803,000 people have been deemed eligible for Medicaid or the Children’s Health Insurance Program because of the ACA.
Hot Energy Stocks To Own For 2015: Telus Corporation(TU)
TELUS Corporation provides telecommunications products and services primarily in Canada. Its telecommunications products and services include wireless, data, Internet protocol (IP), voice, and television. The company operates through two segments, Wireless and Wireline. The Wireless segment provides digital personal communications, equipment sales, and wireless Internet services. The Wireline segment offers voice local and voice long distance services; data services, which include television, and managed and legacy data services, as well as Internet, enhanced data, and hosting services; and other telecommunications services. TELUS Corporation was founded in 1993 and is based in Burnaby, Canada.
Advisors' Opinion:- [By Tom Taulli]
Big competitors for BCE include Rogers Communications (RCI) and Telus (TU), though it also faces niche players such as Public Mobile, Wind Mobile and Mobilicity. Until recently, there was buzz that Verizon (VZ) might enter the market by buying up the latter two, though VZ apparently scrapped plans for Canadian expansion until 2014.
10 Best Tech Stocks To Own For 2014: Cell Therapeutics Inc (CTIC)
Cell Therapeutics, Inc. (CTI), incorporated in 1991, develops, acquires and commercializes treatments for cancer. The Company�� research, development, acquisition and in-licensing activities concentrate on identifying and developing new ways to treat cancer. As of December 31, 2011, CTI focused its efforts on Pixuvri (pixantrone dimaleate) (Pixuvri), OPAXIO (paclitaxel poliglumex) (OPAXIO), tosedostat, brostallicin and bisplatinates. As of December 31, 2011, it developed Pixuvri, an anthracycline derivative for the treatment of hematologic malignancies and solid tumors. Another late-stage drug candidate of the Company, OPAXIO, is being studied as a potential maintenance therapy for women with advanced stage ovarian cancer, who achieve a complete remission following first-line therapy with paclitaxel and carboplatin. As of December 31, 2011, it also developed tosedostat in collaboration with Chroma Therapeutics, Ltd. (Chroma). On May 31, 2012, CTI completed its acquisition gaining worldwide rights to S*BIO Pte Ltd.'s (S*BIO) pacritinib.
Pixuvri
As of December 31, 2011, the Company developed Pixuvri, an aza-anthracenedione derivative, for the treatment of non-Hodgkin�� lymphoma (NHL), and various other hematologic malignancies, and solid tumors. Pixuvri was studied in the Company�� EXTEND, or PIX301, clinical trial, which was a phase III single-agent trial of Pixuvri for patients with relapsed, refractory aggressive NHL who received two or more prior therapies and who were sensitive to treatment with anthracyclines. On September 28, 2011, CTI announced that a second independent radiology assessment of response and progression endpoint data from its PIX301 clinical trial of Pixuvri was achieved with statistical significance. The results of the EXTEND trial met its primary endpoint and showed that patients randomized to treatment with Pixuvri achieved a significantly higher rate of confirmed and unconfirmed complete response compared to patients treated with standard chem! otherapy had a significantly increased overall response rate and experienced a statistically significant improvement in median progression free survival. Pixuvri had predictable and manageable toxicities when administered at the proposed dose and schedule in the EXTEND clinical trial in heavily pre-treated patients. In March 2011, the Company initiated the PIX-R trial to study Pixuvri in combination with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Pixuvri has also been studied in patients with HER2-negative metastatic breast cancer who have tumor progression after at least two, but not more than three, prior chemotherapy regimens. In the second quarter of 2010, the NCCTG opened this phase II study for enrollment. The study is closed to accrual and results are expected to be reported by the NCCTG later in 2012.
OPAXIO
OPAXIO is the Company�� biologically-enhanced chemotherapeutic agent that links paclitaxel to a biodegradable polyglutamate polymer, resulting in a new chemical entity. As of December 31, 2011, the Company focused its development of OPAXIO on ovarian, brain, esophageal, head and neck cancer. OPAXIO was designed to improve the delivery of paclitaxel to tumor tissue while protecting normal tissue from toxic side effects. In November 2010, results were presented by the Brown University Oncology Group from a phase II trial of OPAXIO combined with temozolomide (TMZ), and radiotherapy in patients with newly-diagnosed, high-grade gliomas, a type of brain cancer. The trial demonstrated a high rate of complete and partial responses and a high rate of six month progression free survival (PFS). Based on these results, the Brown University Oncology Group has initiated a randomized, multicenter, phase II study of OPAXIO and standard radiotherapy versus TMZ and radiotherapy for newly diagnosed patients with glioblastoma with an active gene termed MGMT that reduces responsiveness to TMZ. A phase I/II study of OPAXIO combined with radi! otherapy ! and cisplatin was initiated by SUNY Upstate Medical University, in patients with locally advanced head and neck cancer.
Tosedostat
In March 2011, the Company entered into a co-development and license agreement with Chroma Therapeutics, Ltd. (Chroma), providing the Company with marketing and co-development rights to Chroma�� drug candidate, tosedostat, in North, Central and South America. Tosedostat is an oral, aminopeptidase inhibitor that has demonstrated anti-tumor responses in blood related cancers and solid tumors in phase I-II clinical trials. Interim results from the phase II OPAL study of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia (AML) showed that once-daily, oral doses of tosedostat had predictable and manageable toxicities and results demonstrated response rates, including a high-response rate among patients who received prior hypomethylating agents, which are used to treat myelodysplastic syndrome (MDS), a precursor of AML.
Brostallicin
As of December 31, 2011, the Company developed brostallicin through its wholly owned subsidiary, Systems Medicine LLC, which holds rights to use, develop, import and export brostallicin. Brostallicin is a synthetic deoxyribonucleic acid (DNA) minor groove binding agent that has demonstrated anti-tumor activity and a favorable safety profile in clinical trials, in which more than 230 patients have been treated as of December 31, 2011. The Company uses a genomic-based platform to guide the development of brostallicin. A phase II study of brostallicin in relapsed, refractory soft tissue sarcoma met its predefined activity and safety hurdles and resulted in a first-line phase II clinical trial study that was conducted by the European Organization for Research and Treatment of Cancer (EORTC).
The Company competes with Bristol-Myers Squibb Company, Sanofi-Aventis, Pfizer, Roche Group, Genentech, Inc., Astellas Pharma, Eli Lilly and Company, Celgene, Telik, I! nc., TEVA! Pharmaceuticals Industries Ltd. and PharmaMar.
Advisors' Opinion:- [By Sean Williams]
Cell Therapeutics (NASDAQ: CTIC )
Certainly no discussion of companies with large accumulated deficits would be complete without discussing a biotechnology company. It's perfectly understandable to see a biotech, especially a clinical-stage one, run with an accumulated deficit, as it takes time and money to build up a drug pipeline. However, after multiple complete response letters (the equivalent of a rejection) by the Food and Drug Administration and years without an approved drug, Cell Therapeutics racked up an astounding $1.83 billion in accumulated deficits through the end of fiscal 2012. By comparison, that's nearly 56 times larger than its shareholder equity.� - [By Nathalie Tadena]
Among the companies with shares expected to actively trade in Friday’s session are Vanda Pharmaceuticals Inc.(VNDA), Kimberly-Clark(KMB) and Cell Therapeutics(CTIC).
10 Best Tech Stocks To Own For 2014: Black Box Corporation(BBOX)
Black Box Corporation provides network infrastructure services for communications systems worldwide. Its services include design, installation, integration, monitoring, and maintenance of voice, data, and integrated communications systems. The company also offers voice communications solutions, technology product solutions, premises cabling, and other data-related services, as well as provides technical support services for its solutions, which include hotline services, consultation, site surveys, design and engineering, project management, single-site and multi-site installations, remote monitoring, and certification and maintenance of voice, data, and integrated communication solutions. It sells its products and services to small organizations, corporations, and institutions through its catalogs, on-site services offices, and Internet Web site. The company was founded in 1973 and is headquartered in Lawrence, Pennsylvania.
Advisors' Opinion:- [By Rich Duprey]
Communications specialist�Black Box (NASDAQ: BBOX ) announced today its third-quarter dividend of $0.09 per share, the same rate it paid last month after raising the quarterly payout 12.5% from $0.08 per share.
- [By Evan Niu, CFA]
What: Shares of Black Box (NASDAQ: BBOX ) have popped today by more than 19% after the company reported earnings and boosted its dividend.
- [By Jake L'Ecuyer]
Top losers in the sector included China Unicom (Hong Kong) (NYSE: CHU), off 4.5 percent, and Black Box (NASDAQ: BBOX), down 3 percent.
Top Headline
The Boeing Company (NYSE: BA) reported better-than-expected first-quarter profit. Boeing's quarterly profit declined to $965 million, or $1.28 per share, from a year-ago profit of $1.11 billion, or $1.44 per share. Its adjusted earnings surged to $1.76 per share compared to $1.73 per share. Its revenue climbed to $20.47 billion versus $18.89 billion. However, analysts were projecting earnings of $1.57 per share on revenue of $20.24 billion. For the full year, Boeing expects adjusted earnings of $7.15 to $7.35 per share.
10 Best Tech Stocks To Own For 2014: Rimage Corporation(RIMG)
Rimage Corporation provides disc publishing and virtual publishing solutions that enable businesses to deliver digital content to their customers and employees worldwide. Its solutions enable delivery of videos, documents, audio files, and images. The company?s digital publishing solutions archive, distribute, and protect content on CDs, DVDs, and Blu-Ray Discs. It also offers a video platform, which captures, manages, and distributes live and on-demand content. The company, through its joint venture with Taiwan Electronic Data Processing Corporation, also provides Medical Disc System, a medical imaging disc publishing solution. Rimage Corporation was founded in 1978 and is headquartered in Minneapolis, Minnesota.
Advisors' Opinion:- [By ShadowStock]
RIMG: Rimage Corporation (RIMG)
"Helps businesses deliver digital content directly and securely to their customers, employees and partners"
Market Cap: $83.72M
Enterprise Value: $16.93M
10 Best Tech Stocks To Own For 2014: Responsys Inc.(MKTG)
Responsys, Inc. provides on-demand software and professional services primarily in North America, the Asia Pacific, and Europe. The company offers Responsys Interact suite, a software-as-a-service platform that provides marketers with a set of integrated applications to create, execute, optimize, and automate marketing campaigns in various channels, including email, mobile, social, and the Web. Its platform also leverages third-party applications and data from real-time sources allowing customers to deliver targeted content to its customers and known prospects as part of their interactive marketing campaigns. In addition, it provides professional services, such as strategic, creative, deliverability, campaign, and education services. The company offers its on-demand software and professional services to retail and consumer, travel, financial services, and technology industries through a direct sales force. Responsys, Inc. was founded in 1998 and is headquartered in San Bru no, California.
Advisors' Opinion:- [By The GeoTeam]
Our recent 2013 articles on SaaS companies Selectica (SLTC), E2open (EOPN), Responsys (MKTG), Vocus (VOCS), and ExactTarget (ET) highlighted such opportunities. The average return since the inception of our coverage currently stands at around 34% (55% at their highs).
- [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Responsys (Nasdaq: MKTG ) , whose recent revenue and earnings are plotted below.
10 Best Tech Stocks To Own For 2014: Cvent Inc (CVT)
Cvent, Inc., incorporated on August 20, 1999, is a cloud-based enterprise event management platform. The Company offers an integrated cloud-based software platform that addresses the lifecycle of events and meetings. It provides solutions for both sides of the events and meetings value chain, which include event and meeting planners, and hotels and venues. Its integrated, cloud-based solution addresses the entire event lifecycle by allowing event and meeting planners to organize, market and manage their meetings, conferences, tradeshows and other events. The Company�� online marketplace connects event planners and venues through its vertical search engine that accesses its database of detailed hotel and venue information. It offers six product categories: event management software, strategic meetings management (SMM) software, mobile event apps, pre- and post-event Web surveys, ticketing software and the Cvent Supplier Network (CSN).
The Company offers planners a platform that addresses the lifecycle of events and meetings, including budgeting, planning, venue sourcing, marketing, management and measurement of meetings. The combination of these solutions creates an integrated platform that allows the Company to generate revenue from both sides of the events and meetings value chain. Through the CSN, the Company has created an online marketplace to connect hotels and venues with enterprise event and meeting planners. The Company�� online marketplace, the Cvent Supplier Network (CSN), connects tens of thousands of event and meeting planners seeking the venue for their event with more than 200,000 venues featured in its database.
The Company�� solutions include online event registration; event marketing; budgeting and project management; event logistics and integrations; measurement and reporting, and training and support. Its event marketing solution provides e-marketing tools that allow planners integrate their event marketing and communication process wit! h registration. The Company�� budgeting and project management includes a project management suite that allows for assignment and tracking of event planning tasks. The Company�� event logistics and integrations solution includes tools for table and seating management, name badge and certificate creation, resource and space allocation, speaker management, appointment scheduling, continuing education credit tracking, onsite registration and check-in functionality. Its measurement and reporting platform measures aspects of the event management process. The Company provides training and support to its event management subscription customers, which is available through phone, e-mail and the Internet during the subscription period.
Advisors' Opinion:- [By Jon C. Ogg]
Cvent Inc. (NYSE: CVT) was started as Buy with a $41 price target at Stifel Nicolaus, started as Outperform with a $40 price target at Pacific Crest and started as Buy with a $42 price target at Needham & Company. Shares are up about 1.5% at $36.15
- [By Matt Jarzemsky]
The deal by the data-analysis software maker follows well-received offerings by software makers Workday Inc.(WDAY) and Cvent Inc.(CVT) last week, suggesting investor interest in cloud computing and ��ig data��analysis remain high. Those deals bucked the broader market�� sluggish tone, with indexes little changed out of the gate this year and many strategists predicting muted returns after 2013�� rally.
10 Best Tech Stocks To Own For 2014: Points International Ltd (PCOM)
Points International Ltd. provides a range of e-commerce and technology services to loyalty program operators using. These services consist of a range of e-commerce services (referred as its Loyalty Currency Services) that enable the sale of loyalty currencies (such as frequent flyer miles, hotel points and credit card points), both retail and wholesale. The Company also offers a reward management Website referred to as Points.com. The majority of the Company�� loyalty program partners operate in the United States. It also has a European customer base. It has three wholly owned direct subsidiaries: Points.com Inc., Points International (UK) Limited, and Points International (U.S.) Ltd. The Company�� services are generally delivered through Web-enabled e-commerce solutions. Points.com offers members of multiple loyalty programs the ability to track and manage their loyalty currencies. Advisors' Opinion:- [By Hank Coleman]
Anna Subbotina/Shutterstock You may not be fully aware of it, but you're probably sitting on your own personal treasure hoard: a stash of airline miles, hotel points or reward points you've earned through your credit cards. According to statistics compiled by Points.com and its parent Points International (PCOM), a company specializing in helping consumers trade, exchange and redeem reward points, the average American is hoarding more than 61,000 reward points through various programs. Americans have more than 2.65 billion loyalty memberships -- almost 10 per person. This would be fine if we were spending those points -- but we're not. According to Points.com, only 16 percent of us redeem the points that we earn each year. Why do we love reward points? Is there a danger in hoarding them? What should we do with our points as our balances continue to grow? Why Do We Love Reward Points So Much? Getting something for free is a big allure of reward points and loyalty programs. I love that my airline-branded credit card allows me to check a bag for free. Companies view reward programs as marketing by gamification. If businesses can make patronizing them into a game for their customers, they'll be more likely to do what it takes to advance to the next level. And of course, these programs inspire brand loyalty. I'm a huge fan of Fitbit. I'm always striving for the next badge or level with my fitness goals through the site and its devices. I'm also addicted to checking in to the places that I frequent on Foursquare. It drives me crazy when someone ousts me as the mayor of one of my favorite haunts. Gamification is going on with reward points themselves. Companies have found that we desperately want to get to the next level of rewards. That's why companies have different colored credit cards and exclusive levels that offer even more freebies to loyal customers -- though usually for a price. And we are dreamers. We dream that our frequent flyer miles and hotel rew
No comments:
Post a Comment